Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24529547 | 0.80 | L3MBTL1 (0.33) | L3MBTL1ADORA2AIKBKB | |
| SCHEMBL26040360 | 0.78 | L3MBTL1 (0.37) | L3MBTL1ADORA2AIKBKBIDO1 | |
| SCHEMBL20600838 | 0.76 | CCNE1 (0.33) | L3MBTL1ADORA2A | |
| SCHEMBL11001721 | 0.74 | CYP1A2 (0.38) | L3MBTL1ADORA2AIDO1 | |
| SCHEMBL12618886 | 0.72 | L3MBTL1 (0.37) | L3MBTL1ADORA2AIKBKBIDO1 | |
| SCHEMBL24387271 | 0.72 | KDM1A (0.33) | — | |
| SCHEMBL31291392 | 0.72 | HRH4 (0.33) | L3MBTL1ADORA2AHRH4 | |
| SCHEMBL2424259 | 0.72 | L3MBTL1 (0.42) | L3MBTL1ADORA2AIKBKBIDO1HRH4 | |
| SCHEMBL31291401 | 0.72 | ADORA2A (0.32) | ADORA2A | |
| SCHEMBL31484412 | 0.71 | L3MBTL1 (0.37) | L3MBTL1ADORA2AIKBKBIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719592-A1 | BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION | Centennial Therapeutics, LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12263163-B2 | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor | Kronos Bio, Inc. (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2024249612-A1 | BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION | CENTENNIAL THERAPEUTICS, LLC (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20230391795-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-12-07 | — | — | US | disclosed |
| EP-4236938-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116600803-A | Macrocyclic urea orexin receptor agonists | 默沙东有限责任公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230158023-A1 | CRYSTALLINE SUCCINATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | GILEAD SCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158023-A1 | CRYSTALLINE SUCCINATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | GILEAD SCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11517570-B2 | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine | Kronos Bio, Inc. (US) | 2022-12-06 | — | — | US | disclosed |
| WO-2022094012-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2016172117-A1 | TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160310490-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-10-27 | — | — | US | disclosed |
| US-20160310490-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-10-27 | — | — | US | disclosed |
| US-9290505-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290505-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160058758-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-03-03 | — | — | US | disclosed |
| US-20160058758-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-03-03 | — | — | US | disclosed |
| WO-2015100217-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| US-20150175616-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-06-25 | — | — | US | disclosed |
| US-20150175616-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11517570-B2 | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine | SYK, LCK, LYN | L3MBTL1 3957/4885ADORA2A 4200/4885IKBKB 17/4885 |
| US-20230158023-A1 | CRYSTALLINE SUCCINATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | SYK, LCK, LYN | L3MBTL1 3957/4885ADORA2A 4200/4885IKBKB 17/4885 |
| US-12263163-B2 | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor | SYK, LCK, LYN | L3MBTL1 4115/4885ADORA2A 4307/4885IKBKB 15/4885 |
| US-20150175616-A1 | SYK INHIBITORS | SYK, BTK, LYN | L3MBTL1 1226/4885ADORA2A 2992/4885IKBKB 33/4885 |
| US-20160310490-A1 | SYK INHIBITORS | SYK, BTK, LYN | L3MBTL1 1226/4885ADORA2A 2992/4885IKBKB 33/4885 |
| US-20230391795-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, CRHR1 | L3MBTL1 4488/4885ADORA2A 221/4885IKBKB 2370/4885 |
| US-20160058758-A1 | SYK INHIBITORS | SYK, BTK, LYN | L3MBTL1 1378/4885ADORA2A 1136/4885IKBKB 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.